Biotechnology executive Mark W. Schwartz, PhD, who previously led Galena Biopharma, Bayhill Therapeutics, and several other biotechnology companies, serves as an advisor to start up biotechnology and device companies such as bioSyntagma, NeoLight, and NuShores. He also provides a host of start-up venture leadership solutions. Accordingly, Mark W. Schwartz possesses extensive knowledge of how to grow companies from the ground up.
Launching a small business is an inherently risky proposition, with many failing to make it past the development stages when bringing a product or service to market. One key to attaining viable growth is to keep debt financing to a minimum. Balancing equity financing, licensing, and taking advantage of existing infrastructure, a top management team can focus on a companies core expertise and avoid unnecessary sending on inefficient infrastructure. Rather than attempting to invent the wheel from scratch, it makes sense to adopt and adapt already available systems, technologies, and networks.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly